From Code to Cure: AI’s Expanding Role in Biotech

Author(s): Roberto Iriondo

Originally published on Towards AI.

Source: Image generated via GPT-4.5

At Google Cloud Next ’25 in Las Vegas, biotech leaders from GenBio AI, Freenome, Earli, and Isomorphic Labs joined a panel discussion titled From Code to Cure: AI for Biotech Startups. Moderated by Scott Penberthy of Google Cloud, the session explored how AI is accelerating drug discovery, advancing diagnostics, and transforming R&D across the life sciences. Speakers shared their perspectives on generative design, multimodal data integration, synthetic biology, and the growing role of foundation models in reshaping the biotech landscape.

What does it mean to bring AI into biology — not just for optimization, but as a fundamental shift in how we understand and engineer life itself?

That question grounded the panel at Google Cloud Next ’25, where leaders from Freenome, GenBio AI, Earli, and Isomorphic Labs shared how they’re using AI to solve long-standing bottlenecks in biotech R&D. Moderated by Scott Penberthy, the panel featured:

Le Song, CTO and Co-Founder, GenBio AIJimmy Lin, CSO, FreenomeCyriac Roeding, CEO, EarliSergei Yakneen, CTO, Isomorphic Labs

The central theme: AI isn’t just making things faster or cheaper. It’s making the impossible possible.

Le Song emphasized the need for a new class of biological foundation models. Historically, machine learning in biology has focused on highly… Read the full blog for free on Medium.

Join thousands of data leaders on the AI newsletter. Join over 80,000 subscribers and keep up to date with the latest developments in AI. From research to projects and ideas. If you are building an AI startup, an AI-related product, or a service, we invite you to consider becoming a sponsor.

Published via Towards AI